<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04527523</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00067948</org_study_id>
    <nct_id>NCT04527523</nct_id>
  </id_info>
  <brief_title>Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only</brief_title>
  <official_title>Incidence of Post-operative Cystoid Macular Edema: A Prospective Study Comparing DMEK, DSEK, and DSO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate and compare incidence of post-operative cystoid macular edema&#xD;
      (CME) after Descemet Membrane Endothelial Keratoplasty (DMEK), Descemet's Stripping Automated&#xD;
      endothelial Keratoplasty (DSEK) and Descemet Stripping Only (DSO).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients that are undergoing any of these procedures will be asked if they are willing to&#xD;
      have a baseline pre-operative Optical Coherence Tomography (OCT) scan completed within 4&#xD;
      weeks of surgery. Additional OCT scans will be collected during routine follow up care. It is&#xD;
      hypothesized that the rates of CME will be lower with DSO compared to DMEK and DSEK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Post-Op CME</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>The frequency (number of Subjects) of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Post-Op CME</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>The frequency (number of Subjects) of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Post-Op CME</measure>
    <time_frame>6 weeks post-operative</time_frame>
    <description>The severity of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO that experience Cystoid Macular Edema after surgery - measured by net change of Central Foveal Thickness on Optical Coherence Tomography (OCT- is an imaging technique that uses low-coherence light to capture micrometer-resolution, two- and three-dimensional images from within optical scattering media, e.g., biological tissue)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Post-Op CME</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>The severity of post-operative Cystoid Macular Edema will be evaluated for patients receiving DMEK, DSEK or DSO that experience Cystoid Macular Edema after surgery - measured by net change of Central Foveal Thickness on Optical Coherence Tomography (OCT- is an imaging technique that uses low-coherence light to capture micrometer-resolution, two- and three-dimensional images from within optical scattering media, e.g., biological tissue)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft Detachment</measure>
    <time_frame>6 weeks and 3 months post-operative</time_frame>
    <description>Frequency (number of Subjects) of post-operative graft detachment will be evaluated in patients that receive a corneal endothelial transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-bubbling Procedure</measure>
    <time_frame>6 weeks and 3 months post-operative</time_frame>
    <description>The incidence (number of Subjects) of re-bubbling procedures performed post-operatively will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>6 weeks and 3 month post-operative</time_frame>
    <description>The incidence (number of Subjects) of post-operative infection will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Visual Acuity</measure>
    <time_frame>3 months post-operative</time_frame>
    <description>The Snellen Visual Acuity test - This means that the test subject sees the same line of letters at 20 feet that person with normal vision sees at 20 feet. 20/40 vision means that the test subject sees at 20 feet what a person with normal vision sees at 40 feet.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cystoid Macular Edema</condition>
  <condition>Fuchs Dystrophy</condition>
  <arm_group>
    <arm_group_label>Endothelial Dysfunction Cohort</arm_group_label>
    <description>All patients enrolled in the study will receive a baseline Optical Coherence Tomography scan (OCT) within 4 weeks prior to surgery. Two additional OCT scan will be performed 6 weeks and 3 months after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <description>OCT is an imaging method that uses light waves to create images of the retina.</description>
    <arm_group_label>Endothelial Dysfunction Cohort</arm_group_label>
    <other_name>OCT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with endothelial dysfunction that require treatment, and are being evaluated for&#xD;
        Descemet Stripping Only (DSO), Descemet Membrane Endothelial Keratoplasty (DMEK) or&#xD;
        Descemet's Stripping Automated Endothelial Keratoplasty (DSEK)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient that is undergoing DSO or endothelial corneal transplantation vis DMEK or&#xD;
             DSEK&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients that do not have an optical coherence tomography measurement pre- operatively&#xD;
&#xD;
          -  Patients that don't have an optical coherence tomography measurement post- operatively&#xD;
&#xD;
          -  Patients with a previous history of uncontrolled macular edema&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Giegengack</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Blair Gordy</last_name>
    <phone>336.716.3937</phone>
    <email>bgordy@wakehealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wake Forest Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blair Gordy</last_name>
      <phone>336-716-3937</phone>
      <email>bgordy@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Giegengack</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Inoda S, Hayashi T, Takahashi H, Oyakawa I, Yokogawa H, Kobayashi A, Kato N, Kawashima H. Risk Factors for Cystoid Macular Edema After Descemet Membrane Endothelial Keratoplasty. Cornea. 2019 Jul;38(7):820-824. doi: 10.1097/ICO.0000000000001950.</citation>
    <PMID>30973407</PMID>
  </reference>
  <reference>
    <citation>Kocaba V, Mouchel R, Fleury J, Marty AS, Janin-Manificat H, Maucort-Boulch D, Burillon C. Incidence of Cystoid Macular Edema After Descemet Membrane Endothelial Keratoplasty. Cornea. 2018 Mar;37(3):277-282. doi: 10.1097/ICO.0000000000001501.</citation>
    <PMID>29298168</PMID>
  </reference>
  <reference>
    <citation>Arbelaez JG, Price MO, Price FW Jr. Long-term follow-up and complications of stripping descemet membrane without placement of graft in eyes with Fuchs endothelial dystrophy. Cornea. 2014 Dec;33(12):1295-9. doi: 10.1097/ICO.0000000000000270.</citation>
    <PMID>25299425</PMID>
  </reference>
  <reference>
    <citation>Koenig SB. Planned Descemetorhexis Without Endothelial Keratoplasty in Eyes With Fuchs Corneal Endothelial Dystrophy. Cornea. 2015 Sep;34(9):1149-51. doi: 10.1097/ICO.0000000000000531.</citation>
    <PMID>26186374</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial transplants</keyword>
  <keyword>endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared. Final, overall results will be reported for each outcome.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

